#1 Clinical Trials Search in Europe

Ivacaftor

Ivacaftor, also known as Kalydeco or VX-770, is a groundbreaking medication that has shown promising results in clinical trials for treating cystic fibrosis (CF). This article explores the use of ivacaftor in various clinical trials, its effects on different age groups and CF mutations, and its potential to improve lung function, quality of life, and other important health outcomes for CF patients.

Table of Contents

What is Ivacaftor?

Ivacaftor, also known by its brand names Kalydeco and VX-770, is a groundbreaking medication used to treat certain types of cystic fibrosis (CF)[1]. It was the first drug of its kind to address the underlying cause of CF rather than just treating the symptoms[2].

How Ivacaftor Works

Ivacaftor works by targeting a specific protein called the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). In people with CF, this protein doesn’t function properly, leading to thick, sticky mucus in various organs. Ivacaftor helps to “open” the CFTR protein channels, allowing for better salt and water movement across cell membranes. This action helps to thin the mucus, making it easier to clear from the lungs and other organs[2].

Conditions Treated by Ivacaftor

Ivacaftor is primarily used to treat cystic fibrosis in patients with specific genetic mutations. These include:

  • CFTR gating mutations: Such as G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, and G1349D[3]
  • F508del mutation: When combined with another CFTR mutation that responds to ivacaftor[1]
  • Splicing mutations: In some cases, ivacaftor may be effective for patients with certain splicing mutations[4]

Interestingly, research is also being conducted to explore the potential use of ivacaftor in treating other conditions such as chronic bronchitis and chronic obstructive pulmonary disease (COPD)[5][6].

Effectiveness of Ivacaftor

Clinical trials have shown that ivacaftor can lead to significant improvements in several areas for CF patients:

  • Lung function: Measured by an increase in FEV1 (Forced Expiratory Volume in 1 second), which is the amount of air a person can forcefully exhale in one second[7]
  • Sweat chloride levels: A key diagnostic marker for CF, with lower levels indicating improved CFTR function[7]
  • Quality of life: Measured using the Cystic Fibrosis Questionnaire-Revised (CFQ-R), which assesses respiratory symptoms and overall well-being[7]
  • Weight gain: Improved nutritional status, which is often a challenge for CF patients[7]
  • Reduced pulmonary exacerbations: Fewer episodes of worsening respiratory symptoms[7]

Dosage and Administration

Ivacaftor is typically taken orally, with dosages varying based on age and weight:

  • For patients 6 years and older: 150 mg every 12 hours[8]
  • For children 2 to 5 years old weighing less than 14 kg: 50 mg every 12 hours[8]
  • For children 2 to 5 years old weighing 14 kg or more: 75 mg every 12 hours[8]

It’s important to note that ivacaftor should be taken with fat-containing foods to improve absorption[3].

Side Effects and Safety

While ivacaftor is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Headache
  • Upper respiratory tract infection
  • Stomach pain
  • Diarrhea
  • Rash
  • Nausea
  • Dizziness

More serious side effects, though rare, can include liver problems and cataracts. Regular monitoring of liver function is typically recommended for patients taking ivacaftor[7].

Ongoing Research

Research on ivacaftor continues, with studies exploring its use in younger patients, including infants as young as 4 months old[3]. Additionally, researchers are investigating its potential benefits in treating other conditions beyond cystic fibrosis, such as chronic bronchitis and COPD[5][6].

Aspect Details
Drug Name Ivacaftor (Kalydeco, VX-770)
Target Population CF patients with gating mutations, ages 4 months and older
Primary Outcomes Improved lung function (FEV1), reduced sweat chloride, increased weight/BMI
Secondary Outcomes Improved quality of life, reduced pulmonary exacerbations, better nutritional status
Safety Profile Generally well-tolerated, with ongoing long-term safety studies
Age Groups Studied Infants (4-24 months), children (2-5 years), adolescents, and adults
Potential New Applications Under investigation for chronic bronchitis and COPD

FAQ

  • What is ivacaftor and how does it work? Ivacaftor (also known as Kalydeco or VX-770) is a medication designed to treat cystic fibrosis. It works by improving the function of the defective CFTR protein in people with certain CF mutations, helping to improve the flow of salt and fluids in and out of cells in the lungs and other organs.
  • What types of CF mutations does ivacaftor target? Ivacaftor primarily targets CF patients with gating mutations, such as G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, and G1349D. These mutations allow the CFTR protein to reach the cell surface but impair its function.
  • What are the main benefits observed in clinical trials of ivacaftor? Clinical trials have shown that ivacaftor can improve lung function (measured by FEV1), reduce sweat chloride levels, increase weight and BMI, improve quality of life scores, and decrease the frequency of pulmonary exacerbations in CF patients with responsive mutations.
  • Is ivacaftor effective for all age groups with CF? Clinical trials have evaluated ivacaftor in various age groups, from infants as young as 4 months old to adults. The drug has shown benefits across different age groups, with studies specifically designed for young children, adolescents, and adults with CF.
  • Are there any ongoing studies exploring new uses for ivacaftor? Yes, some clinical trials are investigating the potential use of ivacaftor in treating other conditions such as chronic bronchitis and chronic obstructive pulmonary disease (COPD). These studies aim to determine if ivacaftor's mechanism of action can benefit patients with CFTR dysfunction in diseases other than CF.

Ongoing Clinical Trials on Ivacaftor

  • Evaluation of Safety, Tolerability, and Biodistribution of Inhaled RCT2100 in Cystic Fibrosis: A Phase 1/2 Multicenter Study

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

  • Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany The Netherlands Sweden

  • Study of elexacaftor, tezacaftor and ivacaftor combination therapy to evaluate blood levels in patients with Cystic Fibrosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor in Children and Adults with Cystic Fibrosis Aged 2 Years and Older

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

  • Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy The Netherlands Spain Sweden

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +7

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and leading to various health problems.
  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, the protein affected in cystic fibrosis that regulates the flow of salt and fluids in and out of cells.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Sweat Chloride: A diagnostic test for CF that measures the amount of salt in a person's sweat. High levels indicate CF.
  • Pulmonary Exacerbation: A period of worsening respiratory symptoms in CF patients, often requiring additional treatment.
  • BMI: Body Mass Index, a measure of body fat based on height and weight, used to assess nutritional status in CF patients.
  • Gating Mutation: A type of genetic mutation in CF that allows the CFTR protein to reach the cell surface but impairs its function.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • CFQ-R: Cystic Fibrosis Questionnaire-Revised, a patient-reported outcome measure used to assess quality of life in CF patients.

References

  1. https://clinicaltrials.gov/study/NCT02412111
  2. https://clinicaltrials.gov/study/NCT01117012
  3. https://clinicaltrials.gov/study/NCT03783286
  4. https://clinicaltrials.gov/study/NCT02934698
  5. https://clinicaltrials.gov/study/NCT03251911
  6. https://clinicaltrials.gov/study/NCT04066751
  7. https://clinicaltrials.gov/study/NCT01707290
  8. https://clinicaltrials.gov/study/NCT01946412